

WOOD, PHILLIPS FInd below and/or attached an Office communication of heerning this application or proceeding.

OLD E JCIS		
2 2 7004	Application No.	Applicant(s)
Office Action Summary	09/937,820	BLIND ET AL.
	Examiner	Art Unit
	Heather G. Calamita, Ph.D.	1637
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) Responsive to communication(s) filed on 22 /	A <i>pril 2002</i> .	a succession in
2a)☐ This action is FINAL . 2b)☒ This action is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) Claim(s) 18-35 is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) 18-35 are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) All b) Some * c) None of:		
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 		
Copies of the certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage		
application from the International Bureau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a list of the certified copies not received.		
•		
Attachment(s)	4) 🗖 Into-dam Our	(DTO 412)
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) 🔲 Interview Summary Paper No(s)/Mail Da	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date) 5) Notice of Informal P 6) Other:	ratent Application (PTO-152)
S. Patent and Trademark Office		rt of Paper No./Mail Date 04222004

Application/Control Number: 09/937,820

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 18-29, drawn to a method for identifying an intramer, classified in 435, subclass6.
 - II. Claim 30, drawn to host cell containing one or more vectors having the intramer, classified in class 435, subclass 325.
 - III. Claims 31-32, drawn to a pharmaceutical composition and use classified in class 424, subclass 1.73.
 - IV. Claims 33-34, drawn to the use of a compound which modifies an intracellular target classified in class 435, subclass 6.
 - V. Claim 35, drawn to a diagnostic kit, classified in class 435, subclass 810.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and (II, III, IV & V) are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the method for identifying an intramer can also be used to identify metal ion binding sites in nucleic acids.

Inventions II and (III, IV and V) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case Invention II is drawn to a host cell containing a vector which functions as a means of cloning candidate DNA sequences.

Application/Control Number: 09/937,820

Art Unit: 1637

Invention III is drawn to a pharmaceutical composition that modifies the function of a specific target. Invention IV is related to a use for an unspecified intracellular target. Invention V is drawn to a diagnostic kit.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Heather G. Calamita, Ph.D. whose telephone number is 571.272.2876 and whose e-mail address is heather.calamita@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can normally be reached on weekdays 7:30 A.M. - 4:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571.272.0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 09/937,820

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

hgc

JEFFREY FREDMAN PRIMARY EXAMINER